Ashley Susan Cautillo, MSN CNM | |
1098 W Baltimore Pike Ste 3106, Media, PA 19063-5139 | |
(610) 891-6240 | |
Not Available |
Full Name | Ashley Susan Cautillo |
---|---|
Gender | Female |
Speciality | Midwife |
Location | 1098 W Baltimore Pike Ste 3106, Media, Pennsylvania |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1356803506 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
367A00000X | Advanced Practice Midwife | 25ME00067900 (New Jersey) | Secondary |
176B00000X | Midwife | MW010672 (Pennsylvania) | Primary |
Entity Name | Barnabas Health Medical Group, Pc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1447206420 PECOS PAC ID: 0648172809 Enrollment ID: O20040127000361 |
News Archive
Techulon, Inc. announced today that its Glycofect Discovery and Therapeutic Delivery Platform has been awarded United States patent protection. The patented invention provides a new class of non-viral transfection vectors based on synthetic carbohydrate containing polyamides that can be used for both in vivo and in vitro applications.
Underage drinkers are three times more likely to drink alcohol brands that advertise on television programs they watch compared to other alcohol brands, providing new and compelling evidence of a strong association between alcohol advertising and youth drinking behavior.
Many lives have been lost to the severe pneumonic disease COVID-19 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), during the ongoing pandemic. The reason for the critical lung injury that results in a fatal outcome in a significant minority of patients has been supposed to be the dramatic oversecretion of pro-inflammatory cytokines and chemokines triggered by the virus.
Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announces results from two preclinical studies on entinostat, an orally bioavailable, highly selective, class I histone deacetylase (HDAC) inhibitor, in animal models of breast cancer. The data are being presented as oral poster discussions at the San Antonio Breast Cancer Symposium December 8 through December 12 in San Antonio Texas.
› Verified 5 days ago
Entity Name | Barnabas Health Medical Group Pc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1841557246 PECOS PAC ID: 9537316955 Enrollment ID: O20120820000951 |
News Archive
Techulon, Inc. announced today that its Glycofect Discovery and Therapeutic Delivery Platform has been awarded United States patent protection. The patented invention provides a new class of non-viral transfection vectors based on synthetic carbohydrate containing polyamides that can be used for both in vivo and in vitro applications.
Underage drinkers are three times more likely to drink alcohol brands that advertise on television programs they watch compared to other alcohol brands, providing new and compelling evidence of a strong association between alcohol advertising and youth drinking behavior.
Many lives have been lost to the severe pneumonic disease COVID-19 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), during the ongoing pandemic. The reason for the critical lung injury that results in a fatal outcome in a significant minority of patients has been supposed to be the dramatic oversecretion of pro-inflammatory cytokines and chemokines triggered by the virus.
Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announces results from two preclinical studies on entinostat, an orally bioavailable, highly selective, class I histone deacetylase (HDAC) inhibitor, in animal models of breast cancer. The data are being presented as oral poster discussions at the San Antonio Breast Cancer Symposium December 8 through December 12 in San Antonio Texas.
› Verified 5 days ago
Mailing Address | Practice Location Address |
---|---|
Ashley Susan Cautillo, MSN CNM 1098 W Baltimore Pike Ste 3106, Media, PA 19063-5139 Ph: (610) 891-6240 | Ashley Susan Cautillo, MSN CNM 1098 W Baltimore Pike Ste 3106, Media, PA 19063-5139 Ph: (610) 891-6240 |
News Archive
Techulon, Inc. announced today that its Glycofect Discovery and Therapeutic Delivery Platform has been awarded United States patent protection. The patented invention provides a new class of non-viral transfection vectors based on synthetic carbohydrate containing polyamides that can be used for both in vivo and in vitro applications.
Underage drinkers are three times more likely to drink alcohol brands that advertise on television programs they watch compared to other alcohol brands, providing new and compelling evidence of a strong association between alcohol advertising and youth drinking behavior.
Many lives have been lost to the severe pneumonic disease COVID-19 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), during the ongoing pandemic. The reason for the critical lung injury that results in a fatal outcome in a significant minority of patients has been supposed to be the dramatic oversecretion of pro-inflammatory cytokines and chemokines triggered by the virus.
Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announces results from two preclinical studies on entinostat, an orally bioavailable, highly selective, class I histone deacetylase (HDAC) inhibitor, in animal models of breast cancer. The data are being presented as oral poster discussions at the San Antonio Breast Cancer Symposium December 8 through December 12 in San Antonio Texas.
› Verified 5 days ago